Ambrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
16.12.2022 - Ambrx Biopharma Inc. (Ambrx) (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics platform to create antibody drug conjugates, announced today that it received a notice (the Notice) on ...
Ambrx Adss Ambrx Biopharma Inc Minimum Stock Price Minimum Stock Engineered Precision Private Securities Litigation Reform Act
Source: wallstreet-online.de